APA (7th ed.) Citation

CM, K., YJ, C., YM, C., DY, C., & HH, C. (2025). Major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: A nationwide, population-based cohort study. Therapeutic advances in musculoskeletal disease, 17, 1759720X251321917. https://doi.org/10.1177/1759720X251321917

Chicago Style (17th ed.) Citation

CM, Kao, Chen YJ, Chen YM, Chen DY, and Chen HH. "Major Adverse Cardiovascular Events or Venous Thromboembolism in Patients with Rheumatoid Arthritis Initiating Biological or Targeted Synthetic Disease-modifying Antirheumatic Drugs: A Nationwide, Population-based Cohort Study." Therapeutic Advances in Musculoskeletal Disease 17 (2025): 1759720X251321917. https://doi.org/10.1177/1759720X251321917.

MLA (9th ed.) Citation

CM, Kao, et al. "Major Adverse Cardiovascular Events or Venous Thromboembolism in Patients with Rheumatoid Arthritis Initiating Biological or Targeted Synthetic Disease-modifying Antirheumatic Drugs: A Nationwide, Population-based Cohort Study." Therapeutic Advances in Musculoskeletal Disease, vol. 17, 2025, p. 1759720X251321917, https://doi.org/10.1177/1759720X251321917.